Key words:
Diabetes drugs, diabetes drug investment, diabetes drug report
Special note: This report is exclusively owned by Huajing Viewpoint. In order to ensure the accuracy and authenticity of the report you purchased, please purchase it directly from the market research network. No website or media can reprint or quote! This report is a multi-user report. If you have more requirements, we will modify the research framework of the report and make a reasonable quotation.
The first basic article of diabetes drug industry
The first chapter is an overview of the development of diabetes drug industry.
Section 1 Overview of Diabetes Drugs
Brief introduction and classification of diabetes drugs
Second, the price ratio analysis of diabetes drugs
Third, the general situation of diabetes drug market
4. Comparison between China's diabetes drug market and developed countries.
The current situation and trend of diabetes in the second quarter
First, the current situation and epidemic trend of diabetes in the world
Second, the current situation and epidemic trend of diabetes in China.
Thirdly, the related factors of diabetes in China.
Chapter II Analysis on the Development Trend of Global Diabetes Drug Market in 2009
Section 1 Analysis of Global Diabetes Drug Market in 2009
Second, the growth analysis of the world diabetes drug market
Third, the development analysis of the international new diabetes drug market
Fourth, the trend analysis of major global diabetes drug companies
Section II Analysis of Global Solanesol Market Development in 2009
I. Analysis on the demand of solanesol in the international market in 2009
Second, the international solanesol market growth potential analysis
Third, global solanesol production analysis
Analysis on the Development of Diabetes Drugs in Some Regions and Countries in 2009
First, in 2009, the United States studied the treatment of diabetes with stem cells.
Second, the consumption analysis of diabetes drugs in the UK
Three, Kenya diabetes drug market potential analysis
The third chapter analyzes the investment environment of diabetes drug industry in China in 2009.
Section 1 Analysis of China's Economic Development Environment in 2009
I. Macroeconomic Operation of China in 2009
II. Analysis of Macroeconomic Situation in China in 2009 -20 12
Three. Investment trend and its impact forecast 2009-20 12
In the second quarter, the environmental analysis of diabetes drug policies and regulations in China in 2009.
First, the Ministry of Health and the World Diabetes Foundation signed a cooperation project.
Two, diabetes drugs or included in the list of essential drugs
Three, diabetes external sugar paste products approved for listing.
Four. Description of the Reconstruction of Pioglitazone by Food and Drug Administration in 2009
Section III Analysis of Medical and Health System Reform in China in 2009
I. Tasks and objectives of deepening the reform of the medical and health system
Two. Opinions on deepening the reform of medical and health system
Iii. Analysis of investment planning of medical reform plan in 2009-20 1 1 year
Four, 2009-20 1 1 year medical and health system reform in the near future key implementation plan
The fourth chapter is the dynamic analysis of diabetes drug market in China in 2009.
Section 1 Analysis of the Market Size of Diabetes Drugs in China in 2009
1. Analysis of the market capacity of diabetes drugs in China.
Three, China diabetes drug market development space analysis.
Section III Problems and Countermeasures in the Development of Diabetes Consumer Market in China in 2009
First, online publicity
Second, TV advertising.
Third, community marketing.
Fourth, print media.
Verb (abbreviation for verb) conference marketing
Six, false institutions
Chapter 5: Analysis of the market operation of diabetes drugs in China in 2009.
The first section is the distribution analysis of multinational pharmaceutical companies in the diabetes drug market in China in 2009.
First, the size analysis of the diabetes market in China
Second, the layout of multinational enterprises in China market
Third, the competitive situation of multinational enterprises in China market
Bayer lays out the diabetes drug market in China.
Section II Market Segmentation Trend of Diabetes Drugs in China in 2009
First, the growth trend analysis of patients in China.
Two, China diabetes prevention and control planning.
Third, the influence of price on market competition.
The sixth chapter analyzes the research progress of diabetes drug technology in China in 2009.
Section 1 Design and Development of Innovative Drugs for Diabetes
First, the analysis of new diabetes drugs
Second, the design and development of innovative drugs.
Third, the application and growth analysis of diabetes drug market
Section II Analysis and Prediction of the Research Progress of Diabetes Drugs in 2009
1. Research and Analysis of Insulin Secretion Promoter
Second, the new concept of diabetes drug treatment
Third, prescription drugs for diabetes can improve the efficiency of the immune system.
Section III Analysis and Prediction of the Research Progress of New Insulin Technology in 2009
I. Research progress of new insulin technology in 2009
Second, the breakthrough of new insulin technology in 2009
Third, the breakthrough strategy of multinational companies to deal with new insulin technology
First, the prevalence of diabetes in China.
Second, the investigation and analysis of diabetes in China.
Third, the market prospect of diabetes drug consumption in China
2. Chongqing Heping Pharmacy Chain Co., Ltd.
Three, Tianjin Zhongxin pharmaceutical chain pharmacies
Fourth, Chongqing Tongjunge drugstore chain
The verb (the abbreviation of verb) Shenzhen is consistent.
Six, Sichuan Tiancheng Pharmacy
Seven. Zhonglian pharmacy
Eight, Liaoning Chengda Fiona Fang
Nine, Neptune star
Chapter VIII Analysis on the Operation Trend of Diabetes Drug Subdivision Industry in China in 2009.
I. glipizide
Second, Gliquidone (gliquidone)
3. Gliclazide
Fourth, Glimepiride.
Five, Glibenclamide (glibenclamide)
Six, Tolbutamide (Tolbutamide)
I. Overview of biguanides
Second, the market prospect of biguanide
Part three? Glucosidase inhibitor
Second, the development and analysis of insulin pulmonary inhalers in 2009
Three. Potential analysis of oral insulin in 2009
Section 7 Chinese patent medicines
I. Overview of hypoglycemic Chinese patent medicines
Third, the characteristics and development trend of the domestic oral hypoglycemic drug market
The competition of diabetes drugs
Chapter IX Analysis of the Market Competition Pattern of Diabetes Drug Industry in China in 2009.
Section 1 Analysis of the Market Expansion of Diabetes Drugs by Multinational Pharmaceutical Companies in China
First, the expansion analysis of major multinational pharmaceutical companies
Third, the market competition pattern of Chinese and Western medicines for diabetes
Fourth, the new drug for diabetes treatment, Bibida, was listed in China.
5. New American diabetes drugs entered the domestic market in 2009.
In the second quarter, the competition analysis of domestic enterprises' insulin market in 2009.
First, the impact of high incidence of diabetes on insulin demand
Second, domestic enterprises break through the tight encirclement of foreign goods.
Third, domestic enterprises in the Middle East market competition analysis
Fourthly, the competitive trend analysis of Chinese diabetic drug enterprises.
Chapter 10 Analysis on the Strategy of Improving the Competitiveness of Diabetes Drug Enterprises in China in 2009.
The first part: Analysis of the market competition strategy of diabetes drugs in China in 2009.
First, the leader's market competition strategy
Second, the challenger's market competition strategy
Third, the market competition strategy of followers.
Fourth, the vacancy of market competition strategy.
Monitoring and analysis of diabetes drug advertisements in the second quarter
First, the overall analysis of diabetes drug advertisements
Second, the analysis of print advertisements of diabetes drugs
Third, the analysis of diabetes medication online advertising
Chapter II XI Analysis of financial indicators of competitiveness of key enterprises of diabetes drugs in China in 2009
Section 1 East China Pharmaceutical Group Corporation
I. General situation of the enterprise
Second, the analysis of major economic indicators of enterprises
Third, the analysis of enterprise growth
Fourth, the enterprise management ability analysis
Five, the enterprise profitability and solvency analysis
Section 2 Beijing Shuanghe Pharmaceutical Co., Ltd.
I. General situation of the enterprise
Second, the analysis of major economic indicators of enterprises
Third, the analysis of enterprise growth
Fourth, the enterprise management ability analysis
Five, the enterprise profitability and solvency analysis
Section 3 Shenyang Jishi Pharmaceutical Co., Ltd.
I. Basic information of the enterprise
Second, the enterprise sales revenue and profit level analysis
Three. Analysis of assets and liabilities of enterprises
Four. Enterprise costs and expenses
Section IV Xuzhou Wanbang Biochemical Pharmaceutical Co., Ltd.
I. Basic information of the enterprise
Second, the enterprise sales revenue and profit level analysis
Three. Analysis of assets and liabilities of enterprises
Four. Enterprise costs and expenses
Section 5 Sino-American Shanghai Squibb Pharmaceutical Co., Ltd.
I. Basic information of the enterprise
Second, the enterprise sales revenue and profit level analysis
Three. Analysis of assets and liabilities of enterprises
Four. Enterprise costs and expenses
Section 6 Pfizer Pharmaceutical Co., Ltd.
I. Basic information of the enterprise
Second, the enterprise sales revenue and profit level analysis
Three. Analysis of assets and liabilities of enterprises
Four. Enterprise costs and expenses
Section 7 GlaxoSmithKline Pharmaceutical (Suzhou) Co., Ltd.
I. Basic information of the enterprise
Second, the enterprise sales revenue and profit level analysis
Three. Analysis of assets and liabilities of enterprises
Four. Enterprise costs and expenses
Section 8 Novo Nordisk (China) Pharmaceutical Co., Ltd.
I. Basic information of the enterprise
Second, the enterprise sales revenue and profit level analysis
Three. Analysis of assets and liabilities of enterprises
Four. Enterprise costs and expenses
Section 9 Wenzhou Beipu Technology Co., Ltd.
I. Basic information of the enterprise
Second, the enterprise sales revenue and profit level analysis
Three. Analysis of assets and liabilities of enterprises
Four. Enterprise costs and expenses
Tenth abridgement
The third article is about the related industries of diabetes drugs.
Chapter XII Monitoring and Analysis of Main Indicators of China Pharmaceutical Manufacturing Industry from 2006 to 2009
Section 1 Statistics and Monitoring Analysis of Pharmaceutical Manufacturing Data in China from 2006 to 2008
1.2006-2008 Analysis of the increase in the number of pharmaceutical production enterprises in China.
Two, 2006-2008, China pharmaceutical manufacturing employees survey and analysis.
Three, 2006-2008 China pharmaceutical manufacturing industry total sales revenue analysis.
Four, 2006-2008 China pharmaceutical manufacturing industry total profit analysis.
Five, 2006-2008 China pharmaceutical manufacturing investment assets growth analysis.
Section II Statistics and Monitoring Analysis of the Latest Data of China Pharmaceutical Manufacturing Industry in 2009 (quarterly update)
I. Number and distribution of enterprises
Second, the sales revenue
Three. total profit
Fourth, the number of employees.
Section III Investment Monitoring of Pharmaceutical Manufacturing Industry in China in 2009 (quarterly update)
I. Regional distribution of industrial assets
Two. Comparison of investment growth rate in major provinces and cities
Chapter XIII Statistical Analysis of the Output of Major Drugs in China and Key Provinces and Cities from 2007 to 2009
Section 1 Statistical Analysis of Output Data of Chinese Patent Medicines in 2007-2009
1.2007-2008 output data analysis of Chinese patent medicines in China and key provinces and cities.
2. Analysis of output data of Chinese patent medicines in China and key provinces and cities in 2009.
Three, 2009 China and key provinces and cities of Chinese patent medicine production growth analysis.
Section II Statistical Analysis of Production Data of Chemical Raw Materials in China from 2007 to 2009
1.2007-2008 production data analysis of chemical raw materials in China and key provinces and cities.
2. Analysis of production data of chemical raw materials in China and key provinces and cities in 2009
Three. Analysis on the Growth of Chemical Raw Materials Production in China and Key Provinces and Cities in 2009
Chapter XIV Analysis of Drug Import and Export Trade in China from 20065438+0 to 2009
I. Analysis of drug import data
Second, drug export data analysis
Third, the analysis of drug import and export unit price
Section II Analysis of Drug Import and Export Countries and Regions in 2008-2009
I. Countries and regions importing drugs
Two. Drug exporting countries and regions
Section III Analysis of Drug Import and Export Provinces and Cities in 2008-2009
I. Analysis of the main importing provinces and cities of drugs
Second, the analysis of the main export provinces and cities of drugs
The fourth part is the trend of diabetes drug industry.
Third, the competitive trend of China pharmaceutical market
Four, China pharmaceutical manufacturing industry forecast analysis.
Verb (abbreviation of verb) 2011-The development trend of global pharmaceutical industry in 2020.
Two, the "Eleventh Five-Year Plan" development trend of key areas of medicine
Chapter 16 Analysis of the Development Trend of Diabetes Drug Industry in China from 2065438+00 to 2065438+03.
Section 1 Analysis of the Development Trend of International Diabetes Drug Market in 20 10-20 13 Years
First, the international diabetes drug consumption market trends
Second, the world diabetes drug market forecast in 2065,438+00
Third, the global insulin market scale forecast in 2009-2065,438+00
Four. 20 12 World Drug Market Forecast of Type 2 Diabetes Mellitus
The second quarter 20 10-20 13 analysis of the development trend of diabetes drug market in China.
First, the market prospect analysis of traditional Chinese medicine for reducing blood sugar
Second, the diabetes drug market segment forecast
Third, the prediction of research and development of intelligent drugs for diabetes
Fourth, the layout analysis of multinational pharmaceutical companies The market prospect of diabetes drugs in China.
Article 5 Investment in diabetes drugs
Chapter 17 Analysis on the Investment of Diabetes Drug Industry in China in 2009.
Second, high technology.
Third, high investment.
Fourth, high risk.
Verb (abbreviation for verb) high profitability
Market entry barriers of intransitive verbs
Seven. Concentration degree
Section II Investment Opportunities and Situation of Diabetes Drug Industry in 2009
First, the investment opportunities brought by the 850 billion yuan new medical reform.
Second, the development speed of medicine in 2009 and its investment opportunities
Third, the product profit model of the diabetes market
Chapter 18 20 10-20 13 Investment Opportunities and Risk Analysis of Diabetes Drug Industry in China.
The first section 20 10-20 13 investment risk analysis of diabetes drug industry in China.
1. Transplantation of stem cells is expected to make type I diabetes get rid of insulin.
Second, the research and development progress of new therapies
Third, stem cell transplantation is not suitable for people.
Section 2 20 10-20 13 Opportunities and Challenges of China Diabetes Drug Market Investment.
First, the influence of biological activity on the research and development of diabetes drugs
Second, the development of new drugs for diabetes.
Third, investment opportunities and challenges analysis